For example, KL expression has been shown to exert a protective effect against overall mortality in non-diabetic, pre-dialysis chronic kidney disease (Yang et al., 2020), whereas FGFR2 expression was associated with increased risk of poor prognosis in patients with IPF and lung cancer (Li et al., 2018). This evidence concerns the gene FGFR2 and lung cancer.